Natco Pharma · NSE: NATCOPHARM · BSE: 524816

Q3 FY19 results · Oct–Dec 2018

Natco Pharma reported revenue from operations of ₹556.70 crore and net profit of ₹159.30 crore for Q3 FY19 (Oct–Dec 2018), on a consolidated basis.

Consolidated · ₹ crore
Item	Q3 FY19	Q3 FY18	YoY	Q2 FY19	QoQ
Revenue from operations	556.70	—	—	543.50	+2.4%
Other income	23.30	—	—	40.00	−41.8%
Total income	580.00	—	—	583.50	−0.6%
Profit before tax	204.70	—	—	235.30	−13.0%
Net profit for the period	159.30	—	—	181.60	−12.3%
Attributable to shareholders of the company	159.50	—	—	182.50	−12.6%
EPS, basic (₹)	8.65	—	—	9.89	−12.5%
Net margin (%)	28.6	—		33.4

Standalone · ₹ crore
Item	Q3 FY19	Q3 FY18	YoY	Q2 FY19	QoQ
Revenue from operations	531.90	—	—	522.40	+1.8%
Other income	23.70	—	—	39.70	−40.3%
Total income	555.60	—	—	562.10	−1.2%
Profit before tax	206.40	—	—	246.80	−16.4%
Net profit for the period	162.00	—	—	193.10	−16.1%
EPS, basic (₹)	8.78	—	—	10.47	−16.1%
Net margin (%)	30.5	—		37.0

Consolidated

Standalone